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ABSTRACT
Introduction Individuals with schizophrenia are at a high 
risk of physical health comorbidities and premature mortality. 
Cardiovascular and metabolic causes are an important 
contributor. There are gaps in monitoring, documenting and 
managing these physical health comorbidities. Because of 
their condition, patients themselves may not be aware of 
these comorbidities and may not be able to follow a lifestyle 
that prevents and manages the complications. In many low- 
income and middle- income countries including Pakistan, 
the bulk of the burden of care for those struggling with 
schizophrenia falls on the families.
Objectives To determine the rate of self- reported physical 
health disorders and risk factors, like body mass index 
(BMI) and smoking, associated with cardiovascular and 
metabolic disorders in cases of schizophrenia compared 
with a group of mentally healthy controls.
Design A case- controlled, cross- sectional multicentre 
study of patients with schizophrenia in Pakistan.
Settings Multiple data collection sites across the country 
for patients, that is, public and private psychiatric OPDs 
(out patient departments), specialised psychiatric care 
facilities, and psychiatric wards of teaching and district 
level hospitals. Healthy controls were enrolled from the 
community.
Participants We report a total of 6838 participants’ data 
with (N 3411 (49.9%)) cases of schizophrenia compared 
with a group of healthy controls (N 3427 (50.1%)).
Results BMI (OR 0.98 (CI 0.97 to 0.99), p=0.0025), 
and the rate of smoking is higher in patients with 
schizophrenia than in controls. Problems with vision (OR 
0.13 (0.08 to 0.2), joint pain (OR 0.18 (0.07 to 0.44)) and 
high cholesterol (OR 0.13 (0.05 to 0.35)) have higher 
reported prevalence in controls. The cases describe more 
physical health disorders in the category ‘other’ (OR 
Strengths and limitations of this study
 ► It is a multicentre study, including individuals from 
different geographical locations, ethnicities and so-
cioeconomic class, and uses a strict quality control 
mechanism for data collection.
 ► It is, to our knowledge, the biggest study on physical 
health in schizophrenia in the Pakistani population.
 ► Non- random sampling technique.
 ► Results are based on subjective self- reports which 
can be affected by the variation in the pattern of re-
porting among individuals.
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4.65 (3.01 to 7.18)). This captures residual disorders not listed in the 
questionnaire.
Conclusions Participants with schizophrenia in comparison with controls 
report more disorders. The access in the ‘other’ category may be a 
reflection of undiagnosed disorders.
INTRODUCTION
Individuals suffering from schizophrenia are at an 
increased risk of developing comorbid non- psychiatric 
physical health disorders. This includes infections like 
tuberculosis, HIV, hepatitis B and C,1 2 osteoporosis,3 
digestive system disorders,4 5 respiratory system disor-
ders,6–8 neurological diseases like movement disorders9 10 
and epilepsy.11 12 A World Health Survey assessed the prev-
alence of nine different physical health disorders through 
a large cross- sectional general population study of 242 952 
individuals using random sampling from 48 low/middle- 
income countries (LMICs), including Pakistan. Self- 
reported disorders included arthritis, angina pectoris, 
asthma, diabetes, chronic back pain, visual impairment, 
hearing problems, edentulism and tuberculosis. Twen-
ty- two hundred and twenty- four participants (1.1 %) 
reported that they had been diagnosed with schizo-
phrenia/psychosis. The adjusted OR for individuals with 
psychosis was 4.05 (95% CI 3.25 to 5.04) for multimor-
bidity defined as two or more of these disorders.13
Currently, the most widely studied physical health disor-
ders are cardiovascular and metabolic disease. Several 
systematic reviews and meta- analyses show clear evidence 
of an increase in the risk of 1.4–2 times across all cardio-
vascular and metabolic diseases in individuals suffering 
from schizophrenia,14 resulting in significantly higher 
premature mortality.15 About 60% of the excess mortality 
in severe mental illness, is due to physical health disor-
ders.16 17 The evidence from high- income countries shows 
that the mortality gap between schizophrenia and the 
general population is increasing, mainly due to cardiovas-
cular disease.18 Evidence from LMICs also suggests that 
the average potential years of life lost for persons with 
severe mental illness is about 28 years.19 In a study from 
Ethiopia people with severe mental illness died 30 years 
prematurely and half of these deaths were because of 
infectious diseases.19
Excess morbidity and mortality are a result of some, 
potentially, modifiable risk factors including smoking,20 
obesity21 and sedentary lifestyle.22 Lack of access to appro-
priate healthcare is another contributor.23 24 Patients 
with severe mental illness are less likely to seek help for 
their physical health disorders25 26 and the quality of care 
they receive is inferior to the people without mental 
illness.27–29 In individuals with schizophrenia, chronic 
diseases like diabetes mellitus, dyslipidaemia, hyper-
tension are underdiagnosed and undertreated,30 blood 
pressure and cholesterol are less likely to be recorded by 
general practitioners (GPs).31 Consequences of mental 
illness like cognitive impairment, social isolation and 
suspiciousness may deter patients from seeking help.29 
Individuals with schizophrenia have a higher body mass 
index (BMI) compared with the general population. The 
aetiology includes but is not limited to adverse effects of 
antipsychotics. Other factors involved are pretreatment/
premorbid genetic vulnerabilities, psychosocial and 
socioeconomic risk factors, and an unhealthy lifestyle.32
Most studies from well- developed healthcare systems 
have focused on cardiovascular diseases or metabolic 
disorders in individuals with schizophrenia.33–35 Individ-
uals with psychosis are generally at high risk of multimor-
bidity, including physical health disorders, such as arthritis, 
chronic back pain, which may not increase the risk of prema-
ture mortality, but will have a significant negative impact 
on the quality of life.36 Despite the increased knowledge 
of heightened mortality from high- risk conditions such as 
diabetes, the research on multimorbidity (ie, two or more 
physical health comorbidities) in people with psychosis is 
still limited. The prevalence of and risk factors for devel-
oping disorders of physical health are well established, but 
the data from LMIC is sparse.14
Many studies of physical health disorders in schizo-
phrenia have relied on self- reports.13 37–39 The prevalence 
of smoking has also been assessed with self- reports.40 In 
a US study, there was a consistency between the informa-
tion from Medicaid, Medicare and primary data from self- 
reports, testifying to the validity of patient self- report.39 In 
absence of electronic patient records and variation in the 
quality of case records, self- report is a viable approach to 
gathering information about physical health disorders in 
patients with schizophrenia in Pakistan.
This study is based on self- reported data on phys-
ical health disorders and smoking from a case- control 
study of individuals with schizophrenia. Additionally, we 
measured weight and height to assess the BMI. As part 
of a large, ongoing, multicentre, case- control study of 
the genetics of schizophrenia (GEN- SCRIP: GENetics of 
SChizophRenia In Pakistan), we have assessed comor-
bidity of different physical health disorders, BMI and 
history of smoking. We aim to compare the self- reported 
physical health status of participants with schizophrenia 
with those without this illness.
METHODS
Data presented here were generated from an ongoing, 
genetic case- control study initiated in 2018. The study aims 
to collect 10 000 each of unrelated cases and controls from 
multiple sites in all the regions of Pakistan. Given the diver-
sity of the population, we aimed to represent all the major 
racial groups in our data. Cases were recruited from clinics 
across sites in the country. The clinics were both public 
(ie, government institutions) and private sector. Clinicians 
referred previously diagnosed patients to the research team. 
Comparable controls were recruited from the local commu-
nities by advertising in educational institutions, vocational 
training centres, local malls. Study participants were asked 
to self- report physical health disorders and risk factors for 
cardiovascular and metabolic disease including smoking. 
We also measured the weight and height of the participants 
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to calculate BMI. The data were collected between August 
2018 and September 2019.
Sites
We collected data from 24 sites in the country. Data collec-
tion sites were spread across the country. Table 1 provides 
the provincial details of centres sampled.
Centres were spread across the country, included public 
sector hospitals and clinics and private sector clinics, 
to reach as many ethnic and racial groups as possible. 
Patients were recruited both from outpatients and inpa-
tient departments.
Interviewers
Study interviewers had a graduate- level education in 
psychology or pharmacy. Interviewers received training in 
the administration of the study instruments (Screening 
Questionnaire and Diagnostic Interview for Psychosis 
and Affective Disorders (DI- PAD)).41 We selected these 
instruments to align with our collaborating team in the 
USA who have successfully employed these tools for over 
a decade and in order to make our data comparable to 
theirs. The questions for the Screening Questionnaire 
are from validated instruments and DI- PAD is based on 
questions from Diagnostic Interview for Genetic Studies 
(DIGS),42 a well- validated interview. Our senior diag-
nosticians were trained in New York City by our collabo-
rating team. Senior diagnosticians who took part in initial 
training are three fully trained psychiatrists and one Ph.D. 
scholar. These individuals trained study interviewers. 
Interviews were supervised until inter- rater reliability was 
achieved, measured as Fleiss’ kappa of 0.8 or more. Thus, 
training typically lasted approximately 4 days. We use the 
same stringent quality control system for data collection 
as used by our New York City collaborating team.
Physical health assessment
The physical health assessment consisted of the following 
three aspects.
1. BMI
Both for cases and controls we measured the height 
and weight and used that for calculation of BMI.
2. Assessments of physical health disorders
We used a Screening Questionnaire that has been 
developed for this purpose by our collaborating 
group, the Genomic Psychiatry Cohort Consortium 
in the USA. The consortium was established in 2008 
and they have collected nearly 65 000 participants for 
various studies. They have used the Screening Ques-
tionnaire in these studies. The Screening Question-
naire includes 32 questions and screens for mania, 
psychosis, depression, anxiety disorder, alcohol, 
nicotine and other substance use history. It is based 
on questions from well- validated interviews. The 
Screening Questionnaire also collects demographic 
information (ie, age, gender, and self- identifying race 
and ethnicity), medical conditions and disorders. The 
section on medical conditions starts with the ques-
tion ‘Have you ever been diagnosed with any of these 
medical conditions or disorders?’ and then provides a 
list of disorders, for example, heart problems (exam-
ples: coronary heart disease, myocardial infarction), 
high cholesterol (hypercholesterolaemia). The partic-
ipants can answer yes or no. The last question reads 
‘Any other medical or health problem. If yes, please 
describe:’
During the adaptation of the Screening Question-
naire, we used colloquial language for different dis-
orders. For example, instead of diabetes, we used the 
word ‘sugar’ which is widely understood by laypeople.
3. Smoking status
The Screening Questionnaire has a section on smoking 
that we used for the collection of information about 
smoking.
Psychiatric assessment
For detailed psychopathological assessment of the cases, 
a semistructured interview was conducted using DI- PAD, 
that is, Diagnostic Interview for Psychosis and Affective 
Disorders—an 83 items interview schedule. It contains 
questions about psychopathology for psychotic and affec-
tive disturbances, premorbid adjustments of the patient, 
family history, treatment history and a section for inter-
viewer ratings based on observations during the process. 
The screener and DI- PAD were developed by collabora-
tors in the USA.41 The questions for the DI- PAD are from 
DIGS.42 We translated and back translated the DI- PAD 
and the screener.
The process of translation was managed by a committee 
of bilingual researchers and linguists (AA, AN, MS, FN, 
FH, TN, MA). The instruments were in English and we 
translated them into Urdu. We initially commissioned 
three independent forward translations. These were 
reviewed by the committee and one consensus draft was 
provided to a separate group for back- translation. The 
back- translation was compared with the original draft 
and discrepancies identified were addressed through the 
second iteration of translation. The translation was then 
reviewed by five bilingual researchers in the field and their 
feedback was incorporated in the translated version. We 
then field tested the translated version in 50 participants. 
The feedback from interviewers was incorporated in the 
translation for further improvement. The final translated 
version was approved by the committee.
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The information was gathered through an interview 
with the patients, their accompanying caregiver when 
available, clinical records from the clinic where the 
patient was seen, and information from the treating clin-
ical team.
Participants and data collection
Informed consent was taken from all participants. Patients 
fulfilling theDiagnostic and Statistical Manual of Mental 
Disorders Fifth Edition DSM- V criteria for schizophrenia 
or schizoaffective disorder depressed type were enrolled. 
Exclusion criteria for the cases were (1) poly- substance 
or any other abuse except cannabis before the onset of 
psychosis, (2) acute toxic psychosis, (3) patients with a 
history of severe head injury, (4) onset of schizophrenia 
after the age of 50, (5) neurological disorder before the 
onset of psychotic symptoms, (6) psychotic depression, 
(7) psychotic symptoms secondary to any medical condi-
tions, (8) schizophrenia co- occurring with intellectual 
disability, (9) schizoaffective manic type. A record of the 
excluded patients was also maintained.
Controls
We aimed to enrol controls who did not have a personal or 
family history (in first degree relatives), of schizophrenia, 
major depression, obsessive- compulsive disorder, anxiety 
disorder, intellectual disability or bipolar disorder. We 
administered the Screening Questionnaire to these 
subjects. We used purposive sampling to recruit controls 
from matched communities. The controls had to be unre-
lated biologically to each other and the cases. We iden-
tified controls by advertising in educational institutions, 
professional training institutes and in the community. 
The lower limit for the age in controls was 23.
Quality control
A stepwise standard operating procedure was designed 
and followed to make the process of enrollment uniform 
and alike among all sites. The data entered by inter-
viewers were checked by a trainer/supervisor on daily 
basis and any issues were resolved by a face- to- face or tele-
phone conversation. Ten per cent of patients from each 
centre were randomly selected and recalled for a repeat 
independent interview, by another trainer/supervisor. If 
a centre enrolled less than 100 patients, then we recalled 
a minimum of 10 patients for a second interview. If we 
identified any issues with an interviewer in a centre, we 
provided them additional training.
Data analysis
We used R V.3.6.1 (https:// cran. r- project. org/ bin/ 
windows/ base/ old/ 3. 6. 1/) for data analysis. For cate-
gorical variables, we provide percentages. We performed 
Fisher exact test or t- test as appropriate. We report 
frequencies of various physical health disorders. We 
performed logistic regression with case- control status 
as outcome measure and age and gender as covariates. 
We report ORs and p values for Wald’s test. The other 
category in health issues covers anything not included in 
the list. We calculated BMI from height and weight. We 
used logistic regression with age and gender as covariates 
to examine the differences between cases and controls. 
In the screening questionnaire, there are four ques-
tions about smoking. We report the difference between 
cases and controls and use logistic regression with age 
and gender as covariates. We selected age and gender as 
covariates for these analyses because of prior evidence 
of their effect on physical health disorders, smoking and 
BMI.
Patient or public involvement in study
It was not appropriate or possible to involve patients or 
the public in the design, or conduct, or reporting, or 
dissemination plans of our research.
RESULTS
The schizophrenia cases are diagnosed using DSM- V 
criteria. The total number of cases was 3411 (49.9%) and 
the total number of controls was 3427 (50.1%). The mean 
age of cases was 33.50 (SD 10.0) years and of controls, it 
was 26.04 (SD 6.86) years.
Participants
There were 3411 (49.9%) cases and 3427 (50.1%) 
controls. Among cases, there were 2455 males and 956 
females. In controls, 3032 were males and 395 females. 
The overall proportion of the females is lower than the 
males. The cases were older in age (mean 33.50 years 
(SD10.00)) than controls (mean 26.05 years (SD 6.84)) 
p value<2.2e−16.
Self-reported physical health disorders
Two hundred and eighty- seven (8.38%) among controls 
reported one or more physical health disorders. This 
proportion was higher in cases (n=516, 15.11%). The 
adjusted OR for the difference was 1.26 (CI 1.06 to 1.5) 
with a p value of 0.01.
Table 2 gives details of the 10 most commonly self- 
reported health problems. Case/Control status is the 
outcome measure. To control for multiple comparisons, 
alpha was set at 0.003 as the threshold for significance. 
The ORs are adjusted for age and gender. Cholesterol, 
joint pain and problems with vision were reported more 
frequently by controls. The numbers represent the partic-
ipants who reported that they have been diagnosed 
with the condition, for example, for heart problems 12 
participants in the case group and 8 participants in the 
control group said that they have been diagnosed with 
a heart condition. The ORs are adjusted for age and 
gender. Other problems (an umbrella term for any other 
problem) were higher in cases.
In figure 1, we show the percentage of self- reported 
physical health disorders in cases and controls. Apparent 
access of reported percentage in heart disease, high 
blood pressure, diabetes, digestive system disorders and 
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liver disease is not significant after adjustment for age and 
gender.
The BMI was significantly higher in patients with 
schizophrenia (mean 24.12 (SD 5.02)) compared with 
the control (23.53 mean (SD 3.96); OR 0.98 (CI 0.97 to 
0.99), p=0.00254).
In table 3, we provide the details of responses to ques-
tions about smoking. Smoking was more common in 
cases than in controls.
DISCUSSION
The major findings of the study are that people with 
schizophrenia had significantly higher BMIs and reported 
rates of smoking. The overall number of any physical 
health disorders was higher in cases. Many specific phys-
ical health disorders including cardiovascular system 
disorders did not differ significantly between those diag-
nosed with schizophrenia and the control population 
without a diagnosis of schizophrenia. The adjusted ORs 
of individuals reporting high cholesterol, visual prob-
lems and joint pains favoured controls. The only cate-
gory that was higher in cases was ‘other’. The question 
in the screening questionnaire about the ‘other’ category 
enquired about ‘any other medical or health problem’. 
The ‘other’ category gives the participants a chance to 
describe any other physical health disorder that was not 
listed in the screening questionnaire, for example, heart 
problems (examples: coronary heart disease, myocardial 
infarction), high blood pressure (hypertension), and 
digestive problems (examples: gastrointestinal, celiac 
disease). As expected, response to this question resulted 
in a description of a large number of conditions in collo-
quial language that are difficult to summarise. We present 
this as one category as we suspect that this large number 
of ‘other’ represent unexplored and undiagnosed phys-
ical health disorders.
Table 2 Comparison of self- reported health problems between cases and controls and results of logistic regression
Disorders (N missing) Cases N % Controls N % OR (CI) Adjusted Wald’s p
Heart disease (0) 12 (0.35) 8 (0.23) 0.35 (0.12 to 0.99) 0.048
High BP (0) 113 (3.31) 45 (1.31) 0.92 (0.6 to 1.41) 0.71
Digestive system disorders (4) 112 (3.28) 59 (1.72) 1.54 (1.08 to 2.19) 0.017
Liver disease (3) 59 (1.73) 27 (0.78) 1.36 (0.8 to 2.31) 0.25
Sugar (diabetes) (1) 84 (2.46) 33 (0.96) 0.93 (0.83 to 1.05) 0.24
High cholesterol (2) 7 (0.20) 16 (0.46) 0.13 (0.05 to 0.35) 6.37e–05*
Joint pain (3) 14 (0.41) 18 (0.52) 0.18 (0.07 to 0.44) 0.00022*
Epilepsy (1) 11 (0.32) 3 (0.08) 3.96 (1.01 to 15.53) 0.048
Migraine (20) 29 (0.85) 35 (1.02) 0.64 (0.37 to 1.11) 0.11
Visual problems (0) 36 (1.05) 101 (2.94) 0.13 (0.08 to 0.2) <2e–16*
Other (6) 149 (4.37) 30 (0.87) 4.65 (3.01 to 7.18) 1.43e–11*
*The significant p values are in bold.
Figure 1 Percentage of self- reported physical health disorders in cases and controls.
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Metabolic syndrome
The term metabolic syndrome has been used histori-
cally to describe a group of health conditions leading 
to increased risk of heart diseases and related problems. 
Physically, metabolic syndrome can manifest as increased 
waistline, high blood pressure, increased blood sugar, 
and obesity. The major risk factors for cardiometabolic 
disorders, that is, high BMI and cigarette smoking were 
present but surprisingly, disease conditions such as 
diabetes, high blood pressure and heart disease were not 
significantly higher in the individuals with schizophrenia 
compared with control. This is in contrast to almost 
universally reported findings of higher rates of cardiomet-
abolic disorders in individuals with schizophrenia.14 43 
High rates of metabolic syndrome are reported in those 
suffering from schizophrenia from India and Pakistan. In 
a systematic review of studies of metabolic syndrome from 
India, prevalence of metabolic syndrome in patients with 
schizophrenia was 29.83%. The prevalence in community 
studies was 10.81% and in case- control studies, the OR 
of prevalence was 3.03 in cases compared with controls.44 
In a hospital outpatient- based study from Pakistan with a 
sample size of fifty- six participants, 55.8% had metabolic 
syndrome.45
There are a few possible explanations for this unusual 
finding including under- reporting by participants, and 
under- recognition of these conditions by healthcare 
providers. These explanations are not mutually exclu-
sive. The most likely explanation is the lack of identifi-
cation of cardiometabolic health problems in individuals 
with schizophrenia. Many studies in Europe and North 
America found that cardiovascular problems in individ-
uals with schizophrenia are under- recognised, under- 
recorded and under- treated.24 27 30 35 46 Many barriers 
have been described that can lead to under- reporting 
of the symptoms in schizophrenia. Compared with 
healthy controls individuals with schizophrenia do not 
spontaneously report physical symptoms.47 Symptoms of 
schizophrenia, like cognitive impairment, suspiciousness, 
disorganisation and social isolation can result in lack of 
help- seeking or lack of compliance with care. When they 
seek help, lack of social skills and stigma of mental illness 
may pose additional barriers for them to receive appro-
priate care.48 The support for under- reporting and under- 
recognition of cardiometabolic symptoms comes from 
the finding that the ‘other’ category is reported more 
frequently in cases. This may be representing symptoms 
experienced by patients with schizophrenia that have not 
led to appropriate help- seeking, diagnosis and treatment.
In LMIC like Pakistan, patients with schizophrenia are 
primarily supported by their families. Almost all treatment 
costs are covered from out of pocket expenses. Economic 
reasons are an important factor in non- adherence to 
treatment for schizophrenia in Pakistan49 50 and neigh-
bouring India with similar socioeconomic conditions.51–53 
Physical healthcare may be less of a priority, especially if 
it is not causing acute symptoms. Patients are less likely 
to ask for assessment and treatment. Unless the physical 
health disorders are actively screened and managed, 
recognition of the metabolic syndrome and its compo-
nents will remain low.
Other conditions
A study based on the World Health Survey described self- 
reported conditions from 48 LMICs including Pakistan. 
Nine somatic disorders were examined: arthritis, angina 
pectoris, asthma, diabetes, chronic back pain, visual 
impairment, hearing problems, edentulism and tuber-
culosis. Multimorbidity defined as two or more disorders 
had a significantly higher prevalence in individuals with 
subclinical psychosis, and psychosis.13 This is also consis-
tent with the higher reported prevalence of these phys-
ical health disorders in other literature.54–57 In the case of 
joint pains, the self- reported prevalence was higher in the 
control population, which may reflect a widely reported 
negative association between musculoskeletal conditions 
and schizophrenia.58 Additionally, in the case of painful 
musculoskeletal disorders, it has been postulated that 
people with schizophrenia may be less likely to present 
with painful conditions based on indirect evidence that 
they may experience hypoanalgesia.59
A lower rate of problems with vision has not been 
reported before in people with schizophrenia. There 
are studies to suggest that visual problems are positively 
Table 3 Comparison of cases and controls for smoking
Questions about smoking Cases Controls OR (CI) P value
Over your lifetime, have you smoked more 
than 100 cigarettes? Include cigars, pipes and 
chewing tobacco.
1108/3410 (32.49%) 443/3425 (12.93%) 3.23 (2.86 to 3.67) <2.2e–16
Have you ever had a period of 1 month or more 
when you smoked cigarettes every day?
991/3413 (29.03%) 387/3424 (11.30%) 3.21 (2.81 to 3.66) <2.2e–16
Did you usually smoke your first cigarette within 
1 hour after waking up?
619/3407 (18.16%) 206/3425 (6.01%) 3.46 (2.93 to 4.11) <2.2e–16
Have you ever wanted to quit smoking or have 
tried to quit smoking and found that you could 
not?
449/3408 (13.17%) 253/3424 (7.38%) 1.90 (1.61 to 2.24) 2.894e–15
CI, 95% Confidence Interval; OR, Odds Ratio.
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associated with schizophrenia.54 56 The eye problems 
associated with schizophrenia include eye movement 
disorder,60 strabismus61–64 and visual impairment.65 66 
Certain systemic infections can have eye manifestations 
and can lead to schizophrenia. These include toxoplas-
mosis67 and rubella.68 The possible explanation for a 
higher reported rate in controls in this study is lack of 
awareness among schizophrenia patients about the 
deficits and so lack of help- seeking, investigation and 
treatment.
Clinical implications
Monitoring of physical health should be an integral part 
of the care for individuals with schizophrenia. This can be 
encouraged through clinical audit and training of health-
care providers.
Research implications
Further work that employs assessment of physical health 
by health professionals rather than self- report will provide 
a better estimate of comorbidity in patients with schizo-
phrenia in Pakistan.
Limitations
The strengths of this study include a large sample size with 
a control group a uniform data collection procedures 
by trained assessors with acceptable interrater reliability 
from multiple sites and the use of a methodology and 
instruments that have been well established in previous 
research.41 However, the findings should be interpreted 
in light of a some important limitations. One limitation is 
that the data on physical health was self/family reported, 
without corroboration from other data sources (eg, 
medical records). It was not feasible to conduct full phys-
ical examinations for the number of multi- morbidities 
reported. We did, however, collect information from 
family members in addition to participant self- reports, 
which strengthens our data.
In part due to the diverse, potentially heterogenous 
nature of our sample, there may be a difference in 
reporting patterns between and within the cases and 
controls. However, many factors can influence the 
reporting of physical symptoms and physical disorders. 
For instance, because of cognitive deficits, individuals 
with schizophrenia may be unaware of physical symp-
toms69 70 and antipsychotics reduce the pain sensitivity69 70 
that would affect the reporting of physical health disor-
ders. Additionally, a lack of social skills29 and difficulties in 
communicating physical needs also affect their reporting 
pattern.71
Finally, the patients and controls were not selected 
randomly. For cases, everyone who met the criteria and 
consented was enrolled in the study. Due to the lack 
of services, severe and chronic cases are more likely to 
seek help from psychiatric facilities. This should result in 
higher levels of morbidity in our cases.
Conclusions
We report a large cross- sectional study that shows the self- 
reported physical health disorders in participants with 
schizophrenia. The overall rate of self reported physical 
health disorders was higher in schizophrenia mainly 
because they reported a higher number of problems in 
the ‘other’ category. Apart from a higher rate of increased 
cholesterol among controls, the cardiometabolic symp-
toms were not different between the two groups. However, 
the major risk factors such as BMI and smoking were 
found significantly higher in cases with schizophrenia. 
Prior evidence from the literature suggests that individ-
uals with schizophrenia are less aware of their physical 
health disorders and less likely to seek healthcare. Excess 
of reported disorders in the ‘other’ category may reflect 
disorders that have not been reported to and investigated 
by the healthcare providers.
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